Skip to main content
Lytix Biopharma AS logo

Lytix Biopharma AS — Investor Relations & Filings

Ticker · LYTIX ISIN · NO0010405780 LEI · 549300NXMIMRSBCDZO71 OL Manufacturing
Open in API
Filings indexed 282 across all filing types
Latest filing 2025-04-10 Report Publication Anno…
Country NO Norway
Listing OL LYTIX

About Lytix Biopharma AS

https://www.lytixbiopharma.com/

Lytix Biopharma AS is a clinical-stage immuno-oncology company that develops a proprietary platform of oncolytic molecules for cancer treatment. The company's technology is based on molecules designed to selectively target and lyse cancer cell membranes. This process releases a broad spectrum of tumor antigens, which in turn stimulates a patient's immune system to recognize and attack the cancer, effectively turning immunologically "cold" tumors "hot". Its lead drug candidate, ruxotemitide, is being evaluated in clinical trials as a neoadjuvant treatment for various solid tumors, including melanoma and basal cell carcinoma.

Recent filings

Filing Released Lang Actions
Lytix Biopharma AS: Annual Report for 2024
Report Publication Announcement Classification · 98% confidence The document explicitly states in the title and body: "Lytix Biopharma AS: Annual Report for 2024" and "Lytix Biopharma AS... has today published its Annual Report for 2024". Although it mentions the report is attached, the primary subject and content focus is the Annual Report itself, which corresponds to the 10-K definition (Official yearly report covering company activity and full financial performance). Given the explicit naming convention, 10-K is the most appropriate classification for a comprehensive annual report, even if the announcement format suggests RPA/RNS. However, since the definition for 10-K is 'Official yearly report covering company activity and full financial performance' and the text is clearly summarizing the content of that report, we classify it as the report itself (10-K) rather than just the announcement (RPA), as the document text provides substantial context and highlights from the report. If the text were only a few lines saying 'The 2024 Annual Report is attached,' RPA would be chosen. Here, the length (2100 chars) and content depth lean towards the report classification.
2025-04-10 English
Lytix Biopharma Q4 2024: Solid clinical results strengthen the path to Phase III and further advancements in 2025
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim Report' and covers the fourth quarter and second half-year of 2024. It contains detailed financial statements, including a 'Key figures' table with comparative data for Q4 and H2 2024/2023, as well as a comprehensive operational review of clinical trials and business strategy. It is not merely an announcement or a certification, but a substantive financial report for a period shorter than a full fiscal year. Q4 2024
2025-02-13 English
Lytix Biopharma Q4 2024: Solid clinical results strengthen the path to Phase III and further advancements in 2025
Earnings Release Classification · 100% confidence The document is titled 'Lytix Biopharma Q4 2024: Solid clinical results strengthen the path to Phase III and further advancements in 2025' and details financial highlights (capital raise, cash position) and operational updates (clinical trial progress, management changes) for the fourth quarter of 2024. This structure—a summary of period results, key operational metrics, and financial position—is characteristic of an Earnings Release (ER). It is not a full Annual Report (10-K) or a comprehensive Interim Report (IR), as it focuses on highlights and is explicitly stated as the results published for Q4 2024. The document also mentions a webcast presentation, which is typical for an ER. Q4 2024
2025-02-13 English
Lytix Biopharma Q4 2024: Solid clinical results strengthen the path to Phase III and further advancements in 2025
Earnings Release Classification · 100% confidence The document is titled "Lytix Biopharma Q4 2024: Solid clinical results strengthen the path to Phase III and further advancements in 2025" and explicitly states, "Lytix Biopharma today published the results for the fourth quarter of 2024." It details financial highlights (capital raise) and operational milestones (clinical trial updates) for a specific fiscal period (Q4 2024). This structure strongly indicates a periodic financial results announcement, which aligns with the definition of an Earnings Release (ER). Although it contains more detail than a typical press release, it is focused on the period's results and outlook, rather than being a comprehensive, audited report (10-K) or a detailed management discussion (MDA). The document also mentions a webcast presentation of these results, typical for an ER. Q4 2024
2025-02-13 English
Lytix Biopharma receives Notice of Allowance for U.S. patent application covering its LTX-315 clinical program
Regulatory Filings Classification · 100% confidence The document is a press release from Lytix Biopharma announcing the receipt of a 'Notice of Allowance for U.S. patent application' concerning their LTX-315 clinical program. This announcement relates directly to intellectual property protection and its impact on the company's competitive edge and clinical programs. Among the provided categories, 'Intellectual Property' (IP) is the most fitting classification for news regarding patent grants or allowances, as it directly concerns the company's proprietary rights and assets. The document is not a full financial report (10-K, IR), an earnings release (ER), or a management discussion (MDA). It is a specific announcement about an IP development.
2025-02-12 English
Lytix Biopharma: Invitation to Q4 2024 Results Presentation
Report Publication Announcement Classification · 98% confidence The document is titled 'Lytix Biopharma: Invitation to Q4 2024 Results Presentation' and explicitly states that the company 'will release its fourth quarter 2024 financial results on Thursday, February 13, 2025.' It then provides details for a live webcast presentation to discuss these results, including the date, time, and Q&A instructions. This is not the actual financial report (ER or IR), but rather an announcement about the upcoming release event and presentation. According to Rule 2 (The 'MENU VS MEAL' Rule), a short document announcing the publication or presentation of results falls under Report Publication Announcement (RPA).
2025-02-07 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.